Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Loss of TIMP-1 immune expression and tumor recurrence in localized prostate cancer

Full text
Author(s):
Show less -
dos Reis, Sabrina Thalita [1] ; Viana, Nayara Izabel [1] ; Iscaife, Alexandre [1] ; Pontes-Junior, Jose [1] ; Dip, Nelson [1] ; Antunes, Alberto Azoubel [1] ; Guimaraes, Vanessa Ribeiro [1] ; Santana, Isaque [2] ; Nahas, William Carlos [3] ; Srougi, Miguel [1] ; Moreira Leite, Katia Ramos [2, 1]
Total Authors: 11
Affiliation:
[1] Univ Sao Paulo, Fac Med Sao Paulo, Dept Urol, Lab Invest Med LIM55, BR-05508 Sao Paulo - Brazil
[2] Genoa Biotechnol SA, Sao Paulo - Brazil
[3] Inst Canc Estado Sao Paulo, Sao Paulo - Brazil
Total Affiliations: 3
Document type: Journal article
Source: INTERNATIONAL BRAZ J UROL; v. 41, n. 6, p. 1088-1095, NOV-DEC 2015.
Web of Science Citations: 4
Abstract

Introduction and objective: Overexpression of MMPs has been related to biochemical recurrence after radical prostatectomy. TIMP1 and TIMP2 are controllers of MMPs and the aim of this study is to evaluate the expression levels of MMPs and their regulators using immunohistochemistry in tissue microarray of localized prostate cancer (PC). Materials and Methods: Immune-expression of MMP-9, MMP-2, TIMP1, TIMP-2, MMP-14 and IL8, were analyzed by immunohistochemistry in radical prostatectomy specimens of 40 patients with localized PC who underwent surgery between September 1997 and February 2000. Protein expression was considered as categorical variables, negative or positive. The results of the immune-expression were correlated to Gleason score (GS), pathological stage (TNM), pre-operatory PSA serum levels and biochemical recurrence in a mean follow up period of 92.5 months. Results: The loss of TIMP1 immune-expression was related to biochemical recurrence. When TIMP1 was negative, 56.3% patients recurred versus 22.2% of those whose TIMP1 was positive (p=0.042). MMP-9, MMP-2, IL8 and MMP-14 were positive in the majority of PC. TIMP-2 was negative in all cases. Conclusion: Negative immune-expression of TIMP1 is correlated with biochemical recurrence in patients with PC possibly by failing to control MMP-9, an important MMP related to cancer progression. (AU)